LMN-0801

LMN-0801 is an investigational, orally delivered biologic drug being developed by Lumen Bioscience for the treatment of obesity. It is a potential first-in-class hormone protein produced using a proprietary spirulina-based platform, which allows for scalable and cost-effective manufacturing of therapeutic proteins. LMN-0801 is designed to target metabolic signaling pathways to promote fat loss while specifically preserving lean muscle mass, addressing a significant limitation of current injectable obesity therapies that are often associated with muscle wasting. The drug is currently undergoing clinical evaluation in dose-ranging studies to assess its safety and efficacy in overweight and obese adults.